India has ordered Sun Pharma to halt production of an eye-care drug at one of its plants after quality lapses were found, according to the available report. The action comes as India’s drug manufacturing standards face growing scrutiny at home and overseas.
The country’s pharmaceutical sector has been under increased watch in recent years after locally made cough syrups were linked to the deaths of children in India and in countries including Gambia and Uzbekistan.
No further details on the specific plant, the drug involved or the current status were provided in the input.
